Interestingly, in a recent study, Ramalingam and colleagues analyzed the association of GRK5 Gln41Leu polymorphism with response to β-blocker therapy in a cohort of Indian patients with HF, revealing that patients carrying the Leu41 variant (homozygous and heterozygous forms) presented with reduced events in hospitalization and improved cardiac output, compared to GRK5 Gln41 carriers. Here, GRK5 is linked to hydrops fetalis.